CLINICAL_TRIALS
trial_result
· 2014-01-08
Clinical Trial Update: Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma [Phase 2]
Summary
Phase 2 trial comparing erlotinib to oral etoposide in pediatric ependymoma was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: OSI Pharmaceuticals | Conditions: Recurrent or Refractory Pediatric Ependymoma | Phase 2 | Status: TERMINATED | Results posted: 2014-01-08